Drugs / XO-176
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03516331 | Mar → Aug 2018 | cystic fibrosis | Flatley Discovery Lab LLC | Completed | No outcome recorded |
| Phase 1 | NCT03173573 | Jun 2017 → May 2018 | cystic fibrosis | Flatley Discovery Lab LLC | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03756922 | Nov 2018 → Feb 2020 | cystic fibrosis | Flatley Discovery Lab LLC | Suspended | No outcome recorded Stop: Business |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XO-176 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068547 ↗ |
| Known as | FDL176 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03756922 ↗ |
| Action | Activate | “CFTR potentiator” NCT03756922 ↗ |
| Modality | Small molecule | — CHEMBL6068547 ↗ |
| Route | Oral | “Single and Repeat Oral Doses of FDL176” NCT03173573 ↗ |
| Target | CFTR | “CFTR corrector and potentiator” NCT03516331 ↗ |